Repare Therapeutics
RPTX
RPTX was delisted on the 27th of January, 2026.
54 hedge funds and large institutions have $40.1M invested in Repare Therapeutics in 2024 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 19 reducing their positions, and 11 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less funds holding
Funds holding: 56 → 54 (-2)
4.24% less ownership
Funds ownership: 76.29% → 72.05% (-4.2%)
18% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 11
42% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 19
64% less capital invested
Capital invested by funds: $111M → $40.1M (-$71.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$906K |
| 2 |
Goldman Sachs
New York
|
+$330K |
| 3 |
JP Morgan Chase
New York
|
+$256K |
| 4 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$236K |
| 5 |
BOCH
Blue Owl Capital Holdings
New York
|
+$212K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
-$1.66M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$1.52M |
| 3 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$1.22M |
| 4 |
D.E. Shaw & Co
New York
|
-$515K |
| 5 |
NAMA
Nikko Asset Management Americas
New York
|
-$396K |
RPTX Hedge Fund Activity: Q4 2024 in Review
54 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Repare Therapeutics (RPTX) for Q4 2024, worth a combined $40.1M — down 64% from $111M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of RPTX and 9 opened new positions — a net loss of 2 holders — while 19 trimmed existing stakes and 11 added.
The largest buyer was Aquilo Capital Management, adding an estimated $906K. The largest seller was MPM Asset Management, cutting an estimated $1.66M.
- 54 institutional investors held Repare Therapeutics (RPTX) as of Q4 2024, down from 56 in Q3 2024.
- Funds reported $40.1M of Repare Therapeutics stock for Q4 2024, down 64% quarter-over-quarter.
- 9 funds opened new Repare Therapeutics positions in Q4 2024 and 11 closed out, a net change of -2 holders.
- The largest Repare Therapeutics buyer in Q4 2024 was Aquilo Capital Management, an estimated $906K added.
- The largest Repare Therapeutics seller in Q4 2024 was MPM Asset Management, an estimated $1.66M sold.
Based on aggregated 13F filings for Q4 2024.